Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Innovative pharmacological approach for the treatment of sleep-related breathing disorders

BTG : 29 September, 2006  (Company News)
BTG, the medical innovations company, announced today that it has initiated patient enrolment for a proof of mechanism clinical trial for BGC20-0166, its novel pharmacologic therapy for the treatment of obstructive sleep apnoea. BGC20-0166 targets two distinct mechanisms of serotonin signaling.
BTG, the medical innovations company, announced today that it has initiated patient enrolment for a proof of mechanism clinical trial for BGC20-0166, its novel pharmacologic therapy for the treatment of obstructive sleep apnoea. BGC20-0166 targets two distinct mechanisms of serotonin signaling. As the lead programme in BTG's drug repositioning portfolio, which currently consists of five development programmes involving new therapeutic uses or enhanced formulation of approved drugs, BTG has advanced BGC20-0166 from preclinical validation studies to the current clinical trial in less than eighteen months. The goals of the current clinical study are to investigate the efficacy of BGC20-0166 and to establish mechanistic proof of concept.

'Serotonin signaling has been implicated as playing an important role in the pathophysiology of obstructive sleep apnoea and represents an attractive target for pharmacologic treatment of this serious sleep related respiratory disorder' said Thomas Logan, PhD, Vice President of Drug Repositioning at BTG. 'BGC20-0166 elicited a significant and sustained reduction of apnoea events in multiple preclinical studies indicating its potential as a novel pharmacologic therapy for the effective treatment of obstructive sleep apnoea. Because BGC20-0166 utilises two approved chemical entities, the time to initiation of clinical proof of mechanism was greatly accelerated.'

The study is expected to enroll approximately 30 patients diagnosed with moderate to severe obstructive sleep apnoea and is designed to examine the efficacy of BGC20-0166 in reducing apnoea events as determined by polysomnography. Reduction of the apnoea-hypopnoea index is the primary endpoint of the study, the results of which are expected during the second half of 2006.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo